Veru
VERUVeru Inc. is a late clinical stage biopharmaceutical company specializing in the development of novel medicines for cardiometabolic and inflammatory diseases.
Table of contents
Earnings
Next report
Aug 11, 2026 (in a month)Competitors
By market cap
By revenue growth
By net margin
Profile
Veru Inc. is a late clinical stage biopharmaceutical company specializing in the development of novel medicines for cardiometabolic and inflammatory diseases. The company's core value proposition centers on its drug candidates, enobosarm and sabizabulin, which aim to improve outcomes for patients with obesity and cardiovascular disease. Veru focuses on high-quality weight loss by preserving muscle mass during GLP-1 therapy and addressing residual inflammatory risks in heart disease.
Veru is a late-stage clinical developer targeting high-growth metabolic markets with first-in-class SARMs for muscle preservation.
Questions, answered.
- What is Veru's market cap?
- Veru (VERU) has a market capitalization of $45.1M and trades on NASDAQ.
- Who are Veru's competitors?
- Veru's key competitors include Eli Lilly and Company, Novo Nordisk, Amgen Inc., and others. These companies compete in similar markets and product categories.
- Who does Veru partner with?
- Veru's notable partners include University of Tennessee Research Foundation, Ohio State Innovation Foundation, Eli Lilly and Company, and others.
- What subsidiaries does Veru have?
- Veru's subsidiaries include Aspen Park Pharmaceuticals, Inc..
- Where is Veru headquartered?
- Veru is headquartered in United States of America and employs approximately 233 people. It has been publicly traded since 1990.